lenalidomide has been researched along with gossypol in 3 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (gossypol) | Trials (gossypol) | Recent Studies (post-2010) (gossypol) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 1,810 | 47 | 471 |
| Protein | Taxonomy | lenalidomide (IC50) | gossypol (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 1.1916 | |
| Estrogen receptor 1 | Homo sapiens (human) | 2.5513 | |
| Prolyl endopeptidase | Rattus norvegicus (Norway rat) | 0.28 | |
| Malate dehydrogenase, mitochondrial | Sus scrofa (pig) | 4.2683 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.86 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.86 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.86 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.86 | |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.8268 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.86 | |
| Malate dehydrogenase, cytoplasmic | Sus scrofa (pig) | 4.7683 | |
| DNA-3-methyladenine glycosylase | Homo sapiens (human) | 3 | |
| Caspase-1 | Homo sapiens (human) | 1.23 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 5 | |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | 2.274 | |
| BH3-interacting domain death agonist | Homo sapiens (human) | 2.39 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 2.784 | |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | 1.8192 | |
| L-lactate dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | 2.64 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 0.2725 | |
| L-lactate dehydrogenase | Plasmodium falciparum CDC/Honduras | 4.562 | |
| L-lactate dehydrogenase B chain | Bos taurus (cattle) | 4.562 | |
| L-lactate dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | 2.03 | |
| Inosine-5'-monophosphate dehydrogenase | Pseudomonas aeruginosa PAO1 | 0.9 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.5709 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.2359 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Ailawadhi, S; Borrelo, I; Chanan-Khan, A; Chitta, K; Ersing, N; Khan, AN; Lee, KP; Manfredi, D; Masood, A; Miller, KC; Paulus, A; Sher, T | 1 |
| Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ | 1 |
1 trial(s) available for lenalidomide and gossypol
| Article | Year |
|---|---|
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Gossypol; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thalidomide; Tumor Cells, Cultured | 2012 |
2 other study(ies) available for lenalidomide and gossypol
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2014 |